Inovio Pharmaceuticals Inc Share Price Nyse
Equities
US45773H1023
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 604K 48.14M | Sales 2025 * | 8.03M 640M | Capitalization | 311M 24.79B |
---|---|---|---|---|---|
Net income 2024 * | -99M -7.89B | Net income 2025 * | -93M -7.41B | EV / Sales 2024 * | 515 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 38.7 x |
P/E ratio 2024 * |
-3.12
x | P/E ratio 2025 * |
-3.98
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 24/03/19 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 31/05/02 |
Chief Tech/Sci/R&D Officer | - | 31/01/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 30/11/03 |
Lota Zoth
BRD | Director/Board Member | 64 | 31/12/17 |
Jay Shepard
BRD | Director/Board Member | 66 | 14/01/20 |
1st Jan change | Capi. | |
---|---|---|
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |